Review
doi: 10.1089/hum.2015.018.
The Current and Future Landscape of SERCA Gene Therapy for Heart Failure: A Clinical Perspective
Affiliations
- PMID: 25914929
- DOI: 10.1089/hum.2015.018
Item in Clipboard
Review
The Current and Future Landscape of SERCA Gene Therapy for Heart Failure: A Clinical Perspective
Hum Gene Ther.
2015 May.
Abstract
Gene therapy has been applied to cardiovascular disease for over 20 years but it is the application to heart failure that has generated recent interest in clinical trials. There is laboratory and early clinical evidence that delivery of sarcoplasmic reticulum calcium ATPase 2a (SERCA2a) gene therapy is beneficial for heart failure and this therapy could become the first positive inotrope with anti-arrhythmic properties. In this review we will discuss the rationale for SERCA2a gene therapy as a viable strategy in heart failure, review the published data, and discuss the ongoing clinical trials, before concluding with comments on the future challenges and potential for this therapy.
Similar articles
-
Gene therapy in heart failure. SERCA2a as a therapeutic target.Circ J. 2014;78(11):2577-87. doi: 10.1253/circj.cj-14-1053. Epub 2014 Oct 18. Circ J. 2014. PMID: 25327883 Review.
-
Design of a phase 2b trial of intracoronary administration of AAV1/SERCA2a in patients with advanced heart failure: the CUPID 2 trial (calcium up-regulation by percutaneous administration of gene therapy in cardiac disease phase 2b).JACC Heart Fail. 2014 Feb;2(1):84-92. doi: 10.1016/j.jchf.2013.09.008. Epub 2014 Jan 25. JACC Heart Fail. 2014. PMID: 24622121 Clinical Trial.
-
Intramyocardial injection of SERCA2a-expressing lentivirus improves myocardial function in doxorubicin-induced heart failure.J Gene Med. 2016 Jul;18(7):124-33. doi: 10.1002/jgm.2885. J Gene Med. 2016. PMID: 27203155
-
Sarcoendoplasmic reticulum calcium transport ATPase 2a: a potential gene therapy target in heart failure.Cardiol Rev. 2013 May-Jun;21(3):151-4. doi: 10.1097/CRD.0b013e3182749cdb. Cardiol Rev. 2013. PMID: 23568057 Review.
-
Molecular targets in heart failure gene therapy: current controversies and translational perspectives.Ann N Y Acad Sci. 2012 Apr;1254:42-50. doi: 10.1111/j.1749-6632.2012.06520.x. Ann N Y Acad Sci. 2012. PMID: 22548568 Free PMC article. Review.
Cited by
-
Cardiac Remodeling and Ventricular Pacing: From Genes to Mechanics.Genes (Basel). 2024 May 23;15(6):671. doi: 10.3390/genes15060671. Genes (Basel). 2024. PMID: 38927607 Free PMC article. Review.
-
Urolithin A Protects Hepatocytes from Palmitic Acid-Induced ER Stress by Regulating Calcium Homeostasis in the MAM.Biomolecules. 2024 Nov 26;14(12):1505. doi: 10.3390/biom14121505. Biomolecules. 2024. PMID: 39766212 Free PMC article.
-
Cardiac contractility modulation improves left ventricular systolic function partially via miR-25 mediated SERCA2A expression in rabbit trans aortic constriction heart failure model.J Thorac Dis. 2018 Jun;10(6):3899-3908. doi: 10.21037/jtd.2018.06.22. J Thorac Dis. 2018. PMID: 30069393 Free PMC article.
-
Targeting Calcium Homeostasis in Myocardial Ischemia/Reperfusion Injury: An Overview of Regulatory Mechanisms and Therapeutic Reagents.Front Pharmacol. 2020 Jun 9;11:872. doi: 10.3389/fphar.2020.00872. eCollection 2020. Front Pharmacol. 2020. PMID: 32581817 Free PMC article. Review.
-
Epigallocatechin-3 gallate prevents pressure overload-induced heart failure by up-regulating SERCA2a via histone acetylation modification in mice.PLoS One. 2018 Oct 4;13(10):e0205123. doi: 10.1371/journal.pone.0205123. eCollection 2018. PLoS One. 2018. PMID: 30286210 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
